He is the Director of Research at Gustave Roussy in Villejuif, France, and a Professor of Medicine at the University of Paris-Saclay.
[1][3] From 2010 to 2016, Fabrice André led the Inserm 981/Gustave Roussy/Université Paris-XI joint research unit, focusing on predictive biomarkers and molecular strategies in anticancer therapy.
[1][3] André was elected President of the European Society for Medical Oncology (ESMO) for the 2025–2026 term, having been selected as President-Elect on June 27, 2022.
He leads Phase I-III clinical trials on targeted therapies for breast cancer and oversees large-scale national studies on the implementation of high-throughput technologies in healthcare systems.
[1][2][3][4] He has authored or co-authored 350 scientific publications in international journals and is recognized as a Highly Cited Researcher by the Web of Science Group.